Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.08	0.08	1.03	1.14	0	0
Revenue Growth (YoY)	-10.00%	-92.14%	-9.97%	-	-	-
Gross Profit	0.08	0.08	1.03	1.14	0	0
Selling, General & Admin	12.56	13.33	12	8.08	6.31	5.52
Research & Development	37.46	38.67	23.14	18.03	16.09	16.55
Operating Expenses	50.01	52	35.13	26.11	22.39	22.07
Operating Income	-49.93	-51.92	-34.1	-24.96	-22.39	-22.07
Other Expense / Income	-3.48	-3.1	-1.09	-0.19	-0.18	-0.17
Pretax Income	-46.45	-48.82	-33.02	-24.77	-22.22	-21.9
Net Income	-46.45	-48.82	-33.02	-24.77	-22.22	-21.9
Preferred Dividends	0	0	0	0	0	0
Net Income Common	-46.45	-48.82	-33.02	-24.77	-22.22	-21.9
Shares Outstanding (Basic)	28	27	24	21	12	5
Shares Outstanding (Diluted)	28	27	24	21	12	5
Shares Change	8.52%	10.20%	17.37%	69.51%	143.87%	40.77%
EPS (Basic)	-1.71	-1.83	-1.37	-1.20	-1.83	-4.40
EPS (Diluted)	-1.71	-1.83	-1.37	-1.20	-1.83	-4.40
Free Cash Flow	-39.72	-47.49	8.28	-21	-21.87	-21.53
Free Cash Flow Per Share	-1.42	-1.78	0.34	-1.02	-1.80	-4.33
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-61645.68%	-64098.77%	-3311.07%	-2182.17%	-	-
Profit Margin	-57346.91%	-60269.14%	-3205.53%	-2165.56%	-	-
Free Cash Flow Margin	-49037.04%	-58627.16%	803.69%	-1835.58%	-	-
EBITDA	-45.63	-48.03	-32.32	-24.25	-21.77	-21.48
EBITDA Margin	-56329.63%	-59293.83%	-3137.67%	-2119.76%	-	-
Depreciation & Amortization	0.82	0.79	0.7	0.52	0.45	0.42
EBIT	-46.45	-48.82	-33.02	-24.77	-22.22	-21.9
EBIT Margin	-57346.91%	-60269.14%	-3205.53%	-2165.56%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).